{
    "clinical_study": {
        "@rank": "100844", 
        "arm_group": [
            {
                "arm_group_label": "Active Drug", 
                "arm_group_type": "Experimental", 
                "description": "This group will receive 2 mg (>200lbs), 1.5mg (150-200lbs.) or 1 mg (< 150lbs. of risperidone oral solution on the first day and a placebo on the second day."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Experimental", 
                "description": "This group will receive a placebo on the first day and 2mg (> 200lbs.), 1.5mg (150-200lbs), or 1 mg (<150lbs.) of risperidone oral solution on the second day"
            }
        ], 
        "brief_summary": {
            "textblock": "To detect functional correlation changes in the brain with anti-psychotic drug\n      administration as compared to placebo, and b.) to measure if these changes correlate with\n      the plasma level of anti-psychotic, and c.) to evaluate if these changes correlate with drug\n      induced symptoms and changes in cognitive function."
        }, 
        "brief_title": "Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Imaging of the Brain and Antipsychotics", 
            "Neuronal Network Changes"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Between 18 and 60 years of age\n\n          -  Subject is competent to provide informed consent\n\n        Exclusion Criteria:\n\n          -  Mini Mental Status Exam is less than 28\n\n          -  Past or current history of any psychotic illness in the subject or in first degree\n             family members\n\n          -  Self report of illicit drug use (except marijuana) in the past. Use of marijuana\n             during the last 3 month...\n\n          -  Any use of antipsychotic in the past.\n\n          -  Any neuro-anatomical lesions on previous brain imaging\n\n          -  Any use of D2 receptor blocking agent (such as antiemetics) in the last two weeks.\n\n          -  Any use of any psychotropic medications (SSRI, mood stabilizers, benzodiazepines,\n             stimulants) in the last month.\n\n          -  MRI contraindications\n\n          -  Any cardiovascular or cerebrovascular diseases or conditions that predispose patients\n             to hypotension (eg. dehydration, hypovolemia, antihypertensive medication)\n\n          -  Subjects with diabetes mellitus, metabolic syndrome, hepatic or renal impairment,\n             seizure disorder and any neurological disorder\n\n          -  QTc interval longer than 450 ms for male and 470 ms for female\n\n          -  Subjects who used any medications in the last two weeks (to avoid any possible\n             drug-drug interactions)\n\n          -  Pregnancy\n\n          -  Individuals who are illiterate and/or visually impaired"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01931059", 
            "org_study_id": "13-036"
        }, 
        "intervention": {
            "arm_group_label": [
                "Active Drug", 
                "Placebo"
            ], 
            "intervention_name": "Risperidone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Risperidone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Imaging", 
            "Risperidone", 
            "Placebo", 
            "antipsychotic"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "contact": {
                "email": "margyela@nshs.edu", 
                "last_name": "Miklos Argyelan, MD", 
                "phone": "718-470-8283"
            }, 
            "contact_backup": {
                "email": "nweissman@nshs.edu", 
                "last_name": "Noah Weissman, BA", 
                "phone": "718-470-4152"
            }, 
            "facility": {
                "address": {
                    "city": "Glen Oaks", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "11004"
                }, 
                "name": "Zucker-Hillside Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Miklos Argyelan, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Noah Weissman", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jamie Wagner, BA", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Philip Szeszko, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Anil Malhotra, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers", 
        "other_outcome": {
            "description": "On each trial, participants will view one of four images and will be asked to guess whether it belongs to Category A or B. For each participant, the four images will be randomly assigned to be stimuli S1, S2, S3 and S4. A different set of similar images (S5-S8; S9-S12, etc) will be used for repeated testing. On any given trial, stimuli S1 and S3 will belong to Category A with 90% probability and to Category B with 10% probability, while stimuli S2 and S4 will belong to Category B with 90% probability and to Category A with 10% probability. Stimuli S1 and S2 will be used in the reward-learning task and S3 and S4 in punishment-learning task. Two stimuli per valence will be employed in order to balance category outcome frequencies, so that one stimulus in each task will be associated with each outcome.", 
            "measure": "Feedback-based Probabilistic Classification Task", 
            "safety_issue": "No", 
            "time_frame": "Before every MRI except the 2nd and 4th which will occur during the MRI (5 times - 3 consecutive days)"
        }, 
        "overall_contact": {
            "email": "margyela@nshs.edu", 
            "last_name": "Miklos Argyelan, MD", 
            "phone": "718-470-8283"
        }, 
        "overall_contact_backup": {
            "email": "nweissman@nshs.edu", 
            "last_name": "Noah L Weissman", 
            "phone": "718-470-4152"
        }, 
        "overall_official": {
            "affiliation": "North Shore LIJ Health System", 
            "last_name": "Miklos Argyelan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This will measure the subject's cognitive performance", 
            "measure": "Repeatable Battery for the Assessment of Neuropsychological Status", 
            "safety_issue": "No", 
            "time_frame": "The change of RBANS scores between placebo and treatment conditions on two consequitive days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01931059"
        }, 
        "responsible_party": {
            "investigator_affiliation": "North Shore Long Island Jewish Health System", 
            "investigator_full_name": "Miklos Argyelan, MD", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The secondary outcome measures are the scores from side effect scales (Simpson-Angus Extrapyramidal Side Effects.  It will measured in synchrony with Repeated Battery for the Assessment of Neuropsychological Status to explore if any of these measures would correlate with network changes in the brain.", 
            "measure": "Simpson-Angus Extrapyramidal Side Effects Scale", 
            "safety_issue": "No", 
            "time_frame": "5 times (Before each MRI for 3 consecutive days)"
        }, 
        "source": "North Shore Long Island Jewish Health System", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "North Shore Long Island Jewish Health System", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}